Axsome Therapeutics Inc

NASDAQ:AXSM   3:59:55 PM EDT
58.38
-1.65 (-2.75%)
Regulatory, Earnings Announcements

Axsome Therapeutics Announces Positive Results From The COMET-SI Trial Of AXS-05 In Patients With Major Depressive Disorder Who Have Suicidal Ideation

Published: 12/08/2020 11:09 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Announces Positive Results From the Comet-si Trial of Axs-05 in Patients With Major Depressive Disorder Who Have Suicidal Ideation.
Axsome Therapeutics Inc - 68% Reduction in Madrs Suicidality Item Score by Week 1, and 82% Reduction by Week 4.
Axsome Therapeutics Inc - Resolution of Suicidal Ideation Achieved by 60% of Patients by Week 1, and 78% by Week 4.
Axsome Therapeutics Inc - Rapid and Substantial Improvement in Functioning Achieved by 51% of Patients at Week 1 and 77% of Patients at Week 6.
Axsome Therapeutics Inc - Axs-05 Was Well Tolerated in Comet Trial.
Axsome Therapeutics Inc - Safety Profile of Axs-05 Observed Was Consistent With What Was Previously Reported in Controlled Trials of Axs-05 in Mdd.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.95

Next Quarter Revenue Guidance is expected to be $0.44 Million
Next Quarter EPS Guidance is expected to be -$1.10

More details on our Analysts Page.